Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial.

ABSTRACT:

Background

To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE).

Methods

Single center, explorative trial. Patients with PE were randomized to a single oral dose of sildenafil 50 mg (n?=?10) or placebo (n?=?10) as add-on to conventional therapy. The time from hospital admission to study inclusion was 2.3?±?0.7 days. Right ventricular function was evaluated immediately before and shortly after (0.5-1.5 h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary efficacy endpoint was cardiac index measured by CMR.

Results

Patients had acute intermediate-high risk PE verified by computed tomography pulmonary angiography, systolic blood pressure of 135?±?18 (mean?±?SD) mmHg, increased right ventricular/left ventricular ratio 1.1?±?0.09 and increased troponin T 167?±?144 ng/L. Sildenafil treatment did not improve cardiac index compared to baseline (0.02?±?0.36 l/min/m2, p?=?0.89) and neither did placebo (0.00?±?0.34 l/min/m2, p?=?0.97). Sildenafil lowered mean arterial blood pressure (-?19?±?10 mmHg, p?ConclusionA single oral dose of sildenafil 50 mg did not improve cardiac index but lowered systemic blood pressure in patients with acute intermediate-high risk PE. The time from PE to intervention, a small patient sample size and low pulmonary vascular resistance are limitations of this study that should be considered when interpreting the results.

Trial registration

The trial was retrospectively registered at www.clinicaltrials.gov (NCT04283240) February 2nd 2020, https://clinicaltrials.gov/ct2/show/NCT04283240?term=NCT04283240&draw=2&rank=1 .

SUBMITTER: Andersen A 

PROVIDER: S-EPMC7916297 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature